Abstract | OBJECTIVE: To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement. METHODS: Patients with pSS and PNS involvement who were included in the French AIR registry were analysed. RESULTS: 17 patients (age 60 years (44-78 years); 14 were female) were analysed. Neurological improvement was noted in 11 patients (65%) at 3 months. Rankin scale decreased from 3 (1-5) to 2 (1-5), 2 (1-5) and 2 (1-6) after 3, 6 and 9 months (p=0.02). European Sjögren's Syndrome Disease Activity Index decreased from 18 (10-44) to 11 (5-20), 11 (5-29) and 12 (5-30) after 3, 6 and 9 months (p<0.05). RTX was effective in neurological involvement in 9/10 patients with vasculitis or cryoglobulinaemia (90%) (group 1) at 3 months and in 2/7 cases (29%) without cryoglobulinaemia and vasculitis (p=0.03). Rankin and European Sjögren's Syndrome Disease Activity Index scales decreased significantly in group 1. CONCLUSION: RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.
|
Authors | A Mekinian, P Ravaud, P Y Hatron, C Larroche, J Leone, B Gombert, M Hamidou, A Cantagrel, C Marcelli, S Rist, M Breban, D Launay, O Fain, J E Gottenberg, X Mariette |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 71
Issue 1
Pg. 84-7
(Jan 2012)
ISSN: 1468-2060 [Electronic] England |
PMID | 21926185
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antirheumatic Agents
- Rituximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived
(adverse effects, therapeutic use)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Cryoglobulinemia
(complications, drug therapy)
- Drug Evaluation
(methods)
- Female
- Humans
- Male
- Middle Aged
- Peripheral Nervous System Diseases
(drug therapy, etiology)
- Registries
- Rituximab
- Sjogren's Syndrome
(complications, drug therapy)
- Treatment Outcome
- Vasculitis
(complications, drug therapy)
|